Nanomedicine: Novel approaches in human and veterinary therapeutics

Veterinary Parasitology

Volumn 180, Issue 1-2, 2011, Pages 47-71

  Irache, Juan M ^a   Esparza, Irene ^a   Gamazo, Carlos ^a   Agüeros, Maite ^a   Espuelas, Socorro ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Controlled release; Drug delivery; Nanomedecines; Nanoparticles

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; AMPICILLIN; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BUCRILATE; CIPROFLOXACIN; COPOLYMER; CYCLODEXTRIN; DENDRIMER; DOXORUBICIN; DOXORUBICINE TRANSDRUG; GANCICLOVIR; GENTAMICIN; ISONIAZID; LIPID; LIPOSOME; MACROGOL; NANOCAPSULE; NANOCARRIER; NANOCRYSTAL; NANOPARTICLE; PACLITAXEL; POLYMER; PROTEIN; PYRAZINAMIDE; QUININE; RIFAMPICIN; SMALL INTERFERING RNA; SOLID LIPID NANOPARTICLE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVANCED CANCER; ARTICLE; BACTERIAL INFECTION; BIOCOMPATIBILITY; BIODEGRADABILITY; BIOMIMETICS; BREAST CANCER; CHEMICAL INTERACTION; CLASSIFICATION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG STABILITY; DRUG TARGETING; HUMAN; INFECTION CONTROL; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LISTERIOSIS; LIVER CELL CARCINOMA; LIVER METASTASIS; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MICELLE; MYCOSIS; NANOMEDICINE; NANOPHARMACEUTICS; NANOTECHNOLOGY; NONHUMAN; ORAL DRUG ADMINISTRATION; PARASITOSIS; POWDER; SINGLE DRUG DOSE; SOLID TUMOR; SUSPENSION; VACCINATION; VETERINARY MEDICINE;

ANIMALS; COMMUNICABLE DISEASES; DRUG DELIVERY SYSTEMS; HUMANS; LIPIDS; NANOMEDICINE; NANOPARTICLES; NEOPLASMS; POLYMERS; VACCINATION; VETERINARY MEDICINE;

EID: 79960320791     PISSN: 03044017     EISSN: 18732550     Source Type: Journal    
DOI: 10.1016/j.vetpar.2011.05.028     Document Type: Article

References (292)

1. Agrawal S.K., Sanabria-DeLong N., Coburn J.M., Tew G.N., Bathia S.R. Novel drug release profiles from micellar solutions of PLAPEO-PLA triblock copolymers. J. Controlled Release 2006, 112:64-71.
2. Agüeros M., Ruiz-Gaton L., Vauthier C., Bouchemal K., Espuelas S., Ponchel G., Irache J.M. Combined hydroxypropyl-beta-cyclodextrin and poly(anhydride) nanoparticles improve the oral permeability of paclitaxel. Eur. J. Pharm. Sci. 2009, 38:405-413.
3. Agüeros M., Zabaleta V., Espuelas S., Campanero M.A., Irache J.M. Increased oral bioavailability of paclitaxel by its encapsulation through complex formation with cyclodextrins in poly(anhydride) nanoparticles. J. Controlled Release 2010, 145:2-8.
4. Allemann E., Gurnay R., Doelker E. Preparation of aqueous polymeric nanodispersions by a reversible salting-out process, influence of process parameters on particle size. Int. J. Pharm. 1992, 87:247-253.
5. Allison A.C., Gregoriadis G. Liposomes as immunological adjuvants. Nature 1974, 252:252.
6. Ambruosi A., Yamamoto H., Kreuter J. Body distribution of polysorbate-80 and doxorubicin-loaded [14C]poly(butyl cyanoacrylate) nanoparticles after i.v. administration in rats. J. Drug Target. 2005, 13:535-542.
7. Arangoa M.A., Campanero M.A., Renedo M.J., Ponchel G., Irache J.M. Gliadin nanoparticles as carriers for the oral administration of lipophilic drugs. Relationship between bioadhesion and pharmacokinetics. Pharm. Res. 2001, 18:1521-1527.
8. Araujo L., Lobenberg R., Kreuter J. Influence of the surfactant concentration on the body distribution of nanoparticles. J. Drug Target. 1999, 6:373-385.
9. ® AN as a new polymer for the preparation of ligand-nanoparticle conjugates. J. Controlled Release 2002, 83:321-330.
10. Arbós P., Campanero M.A., Arangoa M.A., Renedo M.J., Irache J.M. Influence of the surface characteristics of PVM/MA nanoparticles on their bioadhesive properties. J. Controlled Release 2003, 89:19-30.
11. Arbós P., Campanero M.A., Arangoa M.A., Irache J.M. Nanoparticles with specific bioadhesive properties to circumvent the pre-systemic degradation of fluorinated pyrimidines. J. Controlled Release 2004, 96:55-65.
12. Arnedo A., Espuelas S., Irache J.M. Albumin nanoparticles as carriers for a phosphodiester oligonucleotide. Int. J. Pharm. 2002, 244:59-72.
13. Arnedo A., Irache J.M., González Gaitano G., Valgañón M., Espuelas S. Bovine serum albumin modified the intracellular distribution and improved the antiviral activity of an oligonucleotide. J. Drug Target. 2003, 11:197-204.
14. Arnedo A., Irache J.M., Merodio M., Espuelas S. Albumin nanoparticles: fusogenic carriers that improved the stability, nuclear accumulation and anticytomegaloviral activity of an oligonucleotide. J. Controlled Release 2004, 94:217-227.
15. Avgoustakis K. Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: preparation, properties and possible applications in drug delivery. Curr. Drug Deliv. 2004, 1:321-333.
16. Bangham A.D., Standish M.M., Watkins J.C. Diffusion of univalent ions across the lamellae of swollen phospholipids. J. Mol. Biol. 1965, 13:238-252.
17. Barratt G. Colloidal drug carriers: achievements and perspectives. Cell Mol. Life Sci. 2003, 60:21-37.
18. Barraud L., Merle P., Soma E., Lefrancois L., Guerret S., Chevallier M., Dubernet C., Couvreur P., Trepo C., Vitvitski L. Increase of doxorubicin sensitivity by doxorubicin loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo. J. Hepatol. 2005, 42:736-743.
19. Berton M., Turelli P., Trono D., Stein C.A., Allémann E., Gurny R. Inhibition of HIV-1 in cell culture by oligonucleotide-loaded nanoparticles. Pharm. Res. 2001, 18:1096-1101.
20. Bhadra D., Bhadra S., Jain P., Jain N.K. Pegnology: a review of PEG-ylated systems. Pharmazie 2002, 57:5-29.
21. Bhavsar M.D., Amiji M.M. Polymeric nano- and microparticle technologies for oral gene delivery. Expert Opin. Drug Deliv. 2007, 4:197-213.
22. Bibby D.C., Talmadge J.E., Dalal M.K., Kurz S.G., Chytil K.M., Barry S.E., Shand D.G., Steiert M. Pharmacokinetics and biodistribution of RGD-targeted doxorubicin loaded nanoparticles in tumor-bearing mice. Int. J. Pharm. 2005, 293:281-290.
23. Bielinska A.U., Kukowska-Latallo J.F., Johnson J., Tomalia D.A., Baker J.R. Regulation of in vitro gene expression using antisense oligonucleotides or antisense expression plasmids transfected using starburst PAMAM dendrimers. Nucleic Acids Res. 1996, 24:2176-2182.
24. Birrenbach, G., 1973. Über Mizellpolymerisate, mögliche Einschlussverbindungen (Nanokapseln) und deren Eignung als Adjuvantien. Dissertation ETH Nr. 5071 (PhD Thesis).
25. Birrenbach G., Speiser P.P. Polymerized micelles and their use as adjuvants in immunology. J. Pharm. Sci. 1976, 65:1763-1766.
26. Bivas-Benita M., Lin M.Y., Bal S.M., van Meijgaarden K.E., Franken K.L., Friggen A.H., Junginger H.E., Borchard G., Klein M.R., Ottenhoff T.H. Pulmonary delivery of DNA encoding Mycobacterium tuberculosis latency antigen Rv1733c associated to PLGA-PEI nanoparticles enhances T cell responses in a DNA prime/protein boost vaccination regimen in mice. Vaccine 2009, 27:4010-4017.
27. Bivas-Benita M., Laloup M., Versteyhe S., Dewit J., De B.J., Jongert E., Borchard G. Generation of Toxoplasma gondii GRA1 protein and DNA vaccine loaded chitosan particles: preparation, characterization, and preliminary in vivo studies. Int. J. Pharm. 2003, 266:17-27.
28. Borges O., Tavares J., de Sousa A., Borchard G., Junginger H.E., Cordeiro-da-Silva A. Evaluation of the immune response following a short oral vaccination schedule with hepatitis B antigen encapsulated into alginate-coated chitosan nanoparticles. Eur. J. Pharm. Sci. 2007, 32:278-290.
29. Bottomley K. Nanotechnology for drug delivery: a validated technology?. Drug Deliv. Rep. (Autumn/Winter) 2006, 20-21.
30. Boudad H., Legrand P., Appel M., Coconier M.H., Ponchel G. Formulation and cytotoxicity of combined cyclodextrin poly(alkylcyanoacrylate) nanoparticles on Caco-2 cells monolayers intended for oral administration of saquinavir. STP Pharm. Sci. 2001, 11:369-375.
31. Bowman K., Leong K.W. Chitosan nanoparticles for oral drug and gene delivery. Int. J. Nanomed. 2006, 1:117-128.
32. Braet F., Dezanger R., Baekeland M., Crabbe E., van der Smissen P., Wisse E. Structure and dynamics of the fenestrae-associated cytoskeleton of rat-liver sinusoidal endothelial cells. Hepatology 1995, 21:180-189.
33. Bunjes H. Lipid nanoparticles for the delivery of poorly water-soluble drugs. J. Pharm. Pharmacol. 2010, 62:1637-1645.
34. Caliceti P., Veronese F.M. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv. Drug Deliv. Rev. 2003, 55:1261-1277.
35. Calvo P., Gouritin B., Villarroya H., Eclancher F., Giannavola C., Klein C., Andreux J.P., Couvreur P. Quantification and localization of PEGylated polycyanoacrylate nanoparticles in brain and spinal cord during experimental allergic encephalomyelitis in the rat. Eur. J. Neurosci. 2002, 15:1317-1326.
36. Carcaboso A.M., Hernandez R.M., Igartua M., Gascon A.R., Rosas J.E., Patarroy M.E., Pedraz J.L. Immune response after oral administration of the encapsulated malaria synthetic peptide SPf66. Int. J. Pharm. 2003, 260:273-282.
37. Cavalli R., Gasco M.R., Chetoni P., Burgalassi S., Saettone M.F. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int. J. Pharm. 2002, 238:241-245.
38. Chen S.C., Jones D.H., Fynan E.F., Farrar G.H., Clegg J.C., Greenberg H.E., Herrmann J.E. Protective immunity induced by oral immunization with a rotavirus DNA vaccine encapsulated in microparticles. J. Virol. 1998, 72:5757-5761.
39. Chiannilkulchai N., Ammoury N., Caillou B., Devissaguet J.P., Couvreur P. Hepatic tissue distribution of doxorubicin loaded nanoparticles after i.v. administration in reticulosarcoma M 5076 metastasis-bearing mice. Cancer Chemother. Pharmacol. 1990, 26:122-126.
40. Conway M.A., Madrigal-Estebas L., McClean S., Brayden D.J., Mills K.H. Protection against Bordetella pertussis infection following parenteral or oral immunization with antigens entrapped in biodegradable particles: effect of formulation and route of immunization on induction of Th1 and Th2 cells. Vaccine 2001, 19:1940-1950.
41. Cossart P. Bacterial invasion: a new strategy to dominate cytoskeleton plasticity. Dev. Cell 2004, 6:314-315.
42. Couvreur P., Kante B., Roland M., Guiot P., Baudin P., Speiser P. Polycyanoacrylate nanocapsules as potential lysosomotropic carriers - preparation, morphological and sorptive properties. J. Pharm. Pharmacol. 1979, 31:331-332.
43. Couvreur P., Puisieux F. Nano-and micro-particles for the delivery of polypeptides and proteins. Adv. Drug Deliv. Rev. 1993, 10:141-162.
44. Couvreur P., Barratt G., Fattal E., Legrand P., Vauthier C. Nanocapsule technology: a review. Crit. Rev. Ther. Drug Carrier Syst. 2002, 19:99-134.
45. Couvreur P., Gref R., Andrieux K., Malvy C. Nanotechnologies for drug delivery: application to cancer and autoimmune diseases. Prog. Solid State Chem. 2006, 34:231-235.
46. Couvreur P., Vauthier C. Nanotechnology: intelligent design to treat complex disease. Pharm. Res. 2006, 23:1417-1450.
47. Cronkhite R.I., Michael J.G. Sub-compartmentalization of the gastrointestinal (GI) immune system determined with microbeads that differ in release properties. Vaccine 2004, 22:2106-2115.
48. Croy S.R., Kwon G.S. Polymeric micelles for drug delivery. Curr. Pharm. Des. 2006, 12:4669-4684.
49. Csaba N., Garcia-Fuentes M., Alonso M.J. The performance of nanocarriers for transmucosal drug delivery. Expert Opin. Drug Deliv. 2006, 3:463-478.
50. D'Emanuelle A., Attwood D. Dendrimer-drug interactions. Adv. Drug Deliv. Rev. 2005, 57:2147-2162.
51. Da Costa M.R., Gamazo C., Irache J.M. Design and influence of γ-irradiation on the biopharmaceutical properties of nanoparticles containing an antigenic complex from Brucella ovis. Eur. J. Pharm. Sci. 2009, 37:563-572.
52. Da Costa M.R., Irache J.M., Blasco J.M., Muñoz M.P., Marín C.M., Jesús Grilló M., Jesús De Miguel M., Barberán M., Gamazo C. Evaluation of particulate acellular vaccines against Brucella ovis infection in rams. Vaccine 2010, 28:3038-3046.
53. Dai S., Sarmiere P.D., Wiggan O., Bamburg J.R., Zhou D. Efficient Salmonella entry requires activity cycles of host ADF and cofilin. Cell. Microbiol. 2004, 6:459-471.
54. Dalle F., Jouault T., Trinel P.A., Esnault J., Mallet J.M., d'Athis P., Poulain D., Bonnin A. Beta-1,2- and alpha-1,2-linked oligomannosides mediate adherence of Candida albicans blastospores to human enterocytes in vitro. Infect. Immun. 2003, 71:7061-7068.
55. Dalwadi G., Sunserland V.B. Purification of PEGylated nanoparticles using tangential flow filtration (TFF). Drug Dev. Ind. Pharm. 2007, 33:1030-1039.
56. Damge C., Vranckx H., Balschmidt P., Couvreur P. Poly(alkyl cyanoacrylate) nanospheres for oral administration of insulin. J. Pharm. Sci. 1997, 86:1403-1409.
57. Damge C., Maincent P., Ubrich N. Oral delivery of insulin associated to polymeric nanoparticles in diabetic rats. J. Controlled Release 2007, 117:163-170.
58. Davis S. Drug delivery systems. Interdisciplinary Sci. Rev. 2000, 25:175-183.
59. De Jaeghere F., Allemann E., Kubel F., Galli B., Cozens R., Doelker E., Gurny R. Oral bioavailability of a poorly water soluble HIV-1 protease inhibitor incorporated into pH-sensitive particles: effect of the particle size and nutritional state. J. Controlled Release 2000, 68:291-298.
60. de Verdiere A.C., Dubernet C., Nemati F., Soma E., Appel M., Ferte J., Bernard S., Puisieux F., Couvreur P. Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles: towards a mechanism of action. Br. J. Cancer 1997, 76:198-205.
61. Dembri A., Montisci M.J., Gantier J.C., Chacun H., Ponchel G. Targeting of 30-azido 30-deoxythymidine (AZT)-loaded poly(isohexylcyanoacrylate) nanospheres to the gastrointestinal mucosa and associated lymphoid tissues. Pharm. Res. 2001, 18:467-473.
62. Desai M.P., Labhasetwar V., Amidon G.L., Levy R.J. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm. Res. 1996, 13:1838-1845.
63. Duclairoir C., Irache J.M., Nakache E., Orecchioni A.M., Chabenat C., Popineau Y. Gliadin nanoparticles: formation, all-trans-retinoic acid entrapment and release, size optimization. Polym. Int. 1999, 79:327-333.
64. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer 2006, 6:688-701.
65. Ekman B., Lofter C., Sjoholm I. Incorporation of macromolecules in microparticles - preparation and characteristics. Biochemistry 1976, 15:5115-5120.
66. Espuelas M.S., Legrand P., Irache J.M., Gamazo C., Orecchioni A.M., Devissaguet J.Ph., Ygartua P. Poly(e-caprolactone) as an alternative way to reduce amphotericin B toxicity. Int J Pharm 1997, 158:19-27.
67. Espuelas M.S., Legrand P., Cheron M., Barratt G., Puisieux F., Devissaguet J.Ph., Irache J.M. Interaction of amphotericin B with polymeric colloids: 1. A spectroscopy study. Colloid Surf. B: Biointerfaces 1998, 11:141-151.
68. Espuelas S., Legrand P., Loiseau P.M., Bories C., Barratt G., Irache J.M. In vitro antileishmanial activity of amphotericin B loaded in poly(e-caprolactone) nanospheres. J. Drug Target. 2002, 10:593-599.
69. Espuelas M.S., Legrand P., Campanero M.A., Appel M., Chéron M., Gamazo C., Barratt G., Irache J.M. Polymeric carriers for amphotericin B: in vitro activity, toxicity and therapeutic efficacy against systemic Candidiasis in neutropenic mice. J. Antimicrob. Chemother. 2003, 52:419-427.
70. Espuelas S., Irache J.M., Gamazo C. Synthetic particulate antigen delivery systems for vaccination. Inmunología 2005, 24:207-223.
71. Ezpeleta I., Irache J.M., Stainmesse S., Gueguen J., Orecchioni A.M. Preparation of vicilin (vegetal protein from Pisum sativum L.) small sized particles by coacervation. Eur. J. Pharm. Biopharm. 1996, 42:36-41.
72. Ezpeleta I., Irache J.M., Stainmesse S., Chabenat C., Gueguen J., Popineau Y., Orecchioni A.M. Gliadin nanoparticles for the controlled release of all-trans retinoic acid. Int. J. Pharm. 1996, 131:191-200.
73. Fattal E., Youssef M., Couvreur P., Andremont A. Treatment of experimental salmonellosis in mice with ampicillin-bound nanoparticles. Antimicrob. Agents Chemother. 1989, 33:1540-1543.
74. Fattal E., Rojas J., Youssef M., Couvreur P., Andremont A. Liposome-entrapped ampicillin in the treatment of experimental murine listeriosis and salmonellosis. Antimicrob. Agents Chemother. 1991, 35:770-772.
75. Fattal E., Vauthier C. Nanoparticles as drug delivery systems. Encyclopedia of Pharmaceutical Technology 2002, 1864-1882. Marcel Dekker, New York. J. Swarbrick, J.C. Boylan (Eds.).
76. Fernandez L., Gonzalez M., Cerecetto H., Santo M., Silber J.J. Solubilization and release properties of dendrimers. Evaluation as prospective drug delivery systems. Supramol. Chem. 2006, 18:633-643.
77. Fessi H., Puisieux F., Devissaguet J.P., Ammoury N., Benita S. Nanocapsule formation by interfacial deposition following solvent displacement. Int. J. Pharm. 1989, 55:R1-R4.
78. Florence A.T., Hillery A.M., Hussain N., Jani P.U. Nanoparticles as carriers for oral peptide absorption: studies on particle uptake and fate. J. Controlled Release 1995, 36:39-46.
79. Florindo H.F., Pandit S., Lacerda L., Gonçalves L.M., Alpar H.O., Almeida A.J. The enhancement of the immune response against S. equi antigens through the intranasal administration of poly-epsilon-caprolactone-based nanoparticles. Biomaterials 2009, 30:879-891.
80. Föger F., Noonpakdee W., Loretz B., Joojuntr S., Salvenmoser W., Thaler M., Bernkop-Schnürch A. Inhibition of malarial topoisomerase II in Plasmodium falciparum by antisense nanoparticles. Int. J. Pharm. 2006, 319:139-146.
81. Fouarge M., Dewulf M., Couvreur P., Rolland M., Vranckx H. Development of dehydroemetine nanoparticles for the treatment of visceral leishmaniasis. J. Microencapsul. 1989, 6:29-34.
82. Fréchet J.M.J. Functional polymers and dendrimers: Reactivity, molecular architecture, and interfacial energy. Science 1994, 263:1710-1715.
83. Fresta M., Fontana G., Bucolo C., Cavallo G., Giammona G., Puglisi G. Ocular tolerability and in vivo bioavailability of poly(ethylene glycol) (PEG)-coated polyethyl-2-cyanoacrylate nanosphere-encapsulated acyclovir. J. Pharm. Sci. 2001, 9:288-297.
84. Fu M.L., Ying S.C., Wu M., Li H., Wu K.Y., Yang Y., Zhang H., Cheng C., Wang Z.Z., Wang X.Y., Lv X.B., Zhang Y.Z., Gao R. Regulating effects of novel CpG chitosan-nanoparticles on immune responses of mice to porcine paratyphoid vaccines. Biomed. Environ. Sci. 2006, 19:315-322.
85. Gao L., Zhang D., Chan M. Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system. J. Nanopart. Res. 2008, 10:845-862.
86. Gasco, M.R.,1993. Method for producing solid lipid microspheres having a narrow size distribution. US Patent 5 250 236.
87. Gaspar R., Preat V., Opperdoes F.R., Rolland M. Macrophage activation by polymeric nanoparticles of polyalkylcyanoacrylates: activity against intracellular Leishmania donovani associated with hydrogen peroxide production. Pharm. Res. 1992, 9:782-787.
88. Gaucher G., Satturwar P., Jones M.C., Furtos A., Leroux J.C. Polymeric micelles for oral drug delivery. Eur. J. Pharm. Biopharm. 2010, 76:147-158.
89. Gbadamosi J.K., Hunter A.C., Moghimi S.M. PEGylation of microspheres generates a heterogeneous population of particles with differential surface characteristics and biological performance. FEBS Lett. 2002, 532:338-344.
90. Gomez S., Gamazo C., San Roman B., Vauthier C., Ferrer M., Irache J.M. Development of a novel vaccine delivery system based on Gantrez nanoparticles. J. Nanosci. Nanotechnol. 2006, 6:3283-3289.
91. Gomez S., Gamazo C., San Roman B., Ferrer M., Sanz M.L., Espuelas S., Irache J.M. Allergen immunotherapy with nanoparticles containing lypopolysaccharide from Brucella ovis. Eur. J. Pharm. Biopharm. 2008, 70:711-717.
92. Gomez S., Gamazo C., San Roman B., Grau A., Espuelas S., Ferrer M., Sanz M.L., Irache J.M. A novel nanoparticulate adjuvant for immunotherapy with Lolium perenne. J. Immunol. Methods 2009, 348:1-8.
93. Gradishar W.J., Tjulandin S., Davidson N., Shaw H., Desai N., Bhar P., Hawkins M., O'Shaughnessy J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 2005, 23:7794-7803.
94. Greco F., Vicent M.J. Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Adv. Drug Deliv. Rev. 2009, 61:1203-1213.
95. Green M.R., Manikhas G.M., Orlov S., Afanasyev B., Makhson A.M., Bhar P., Hawkins M.J. Abraxane, a novel cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann. Oncol. 2006, 17:1263-1268.
96. Gref R., Minamitake Y., Peracchia M.T., Trubetskoy V., Torchilin V., Langer R. Biodegradable long-circulating polymeric nanospheres. Science 1994, 263:1600-1603.
97. Gref R., Minamitake Y., Peracchia M.T., Domb A., Trubetskoy V., Torchilin V., Langer R. Poly(ethylene glycol)-coated nanospheres: potential carriers for intravenous drug administration. Pharm. Biotechnol. 1997, 10:167-198.
98. Gregoriadis G., Ryman B.R. Lysosomal localization of p-fructofuranosidase-containing liposomes injected into rats. Some implications in the treatment of genetic disorders. Biochem. J. 1972, 129:123-133.
99. Grover G.N., Maynard H.D. Protein-polymer conjugates: synthetic approaches by controlled radical polymerizations and interesting applications. Curr. Opin. Chem. Biol. 2010, 14:818-827.
100. Gurny R., Peppas N.A., Harrington D.D., Banker G.S. Development of biodegradable and injectable lattices for controlled release of potent drugs. Drug Dev. Ind. Pharm. 1981, 7:1-25.
101. Haag R., Kratz F. Polymer therapeutics: concepts and applications. Angew. Chem. Int. Ed. 2006, 45:1198-1215.
102. Haas S.E., Bettoni C.C., Oliveira L.K., Guterres S.S., Dalla Costa T. Nanoencapsulation increases quinine antimalarial efficacy against Plasmodium berghei in vivo. Int. J. Antimicrob. Agents 2009, 34:156-161.
103. Harris J.M., Chess R.B. Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov. 2003, 2:214-221.
104. Hawkins M., Soon-Shiong P., Desai N. Protein nanoparticles as drug carriers in clinical medicine. Adv. Drug Deliv. Rev. 2008, 60. 876-855.
105. Herbst G. Das Lymphgefäßsystem und seine Verrichtung 1844, Vandenhoek Ruprecht Göttingen., pp. 333-337.
106. Heredia K.L., Maynard H.D. Synthesis of protein-polymer conjugates. Org. Biomol. Chem. 2007, 5:45-53.
107. Herrmann J.E., Chen S.C., Jones D.H., Tinsley-Bown A., Fynan E.F., Greenberg H.B., Farrar G.H. Immune responses and protection obtained by oral immunization with rotavirus VP4 and VP7 DNA vaccines encapsulated in microparticles. Virology 1999, 259:148-153.
108. Heurtault B., Saulnier P., Pech B., Proust J.E., Benoit J.P. A novel phase inversion-based process for the preparation of lipid nanocarriers. Pharm. Res. 2002, 19:875-880.
109. Heurtault B., Saulnier P., Pech B., Venier-Julienne M.C., Proust J.E., Phan-Tan-Luu R., Benoit J.P. The influence of lipid nanocapsule composition on their size distribution. Eur. J. Pharm. Sci. 2003, 18:55-61.
110. Hillaireau H., Le Doan T., Couvreur P. Polymer-based nanoparticles for the delivery of nucleoside analogues. J Nanosci. Nanotechnol. 2006, 6:2608-2617.
111. Huang S.H. Liposomes in ultrasonic drug and gene vehicle. Adv. Drug Deliv. Rev. 2008, 60:1167-1176.
112. Huynh N.T., Passirani C., Saulnier P., Benoit J.P. Lipid nanocapsules: a new platform for nanomedicien. Int. J. Pharm. 2009, 379:201-209.
113. Ibrahim N.K., Desai N., Legha S., Soon-Shiong P., Theriault R.L., Rivera E., Esmaeli B., Ring S.E., Bedikian A., Hortobagyi G.N., Ellerhorst J.A. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin. Cancer Res. 2002, 8:1038-1044.
114. Igarashi E. Factors affecting toxicity and efficacy of polymeric nanomedicines. Toxicol. Appl. Pharmacol. 2008, 229:121-134.
115. Illum L., Jabbal-Gill I., Hinchcliffe M., Fisher A.N., Davis S.S. Chitosan as a novel nasal delivery system for vaccines. Adv. Drug Deliv. Rev. 2001, 51:81-96.
116. Irache J.M., Durrer C., Duchêne D., Ponchel G. Preparation and characterization of lectin-latex conjugates for specific bioadhesion. Biomaterials 1994, 15:899-904.
117. Irache J.M., Merodio M., Arnedo A., Campanero M.A., Mirchahi M., Espuelas S. Albumin nanoparticles for the intravitreal delivery of anticytomegaloviral drugs. Mini Rev. Med. Chem. 2005, 5:293-305.
118. Irache J.M., Salman H., Gamazo C., Espuelas S. Mannose-targeted systems for the delivery of therapeutics. Expert Opin. Drug Deliv. 2008, 5:703-724.
119. Irache J.M., Salman H., Gomez S., Espuelas S., Gamazo C. Poly(anhydride) nanoparticles as adjuvants for mucosal vaccination. Front. Biosci. 2010, 2:876-890.
120. Irshad S., Masey N. Considerations when choosing oral chemotherapy: identifying and responding to patient need. Eur. J. Cancer Care 2010, 19:5-11.
121. Ishikawa M., Yoshii H., Furuta T. Interaction of modified cyclodextrins with cytochrome P-450. Biosci. Biotechnol. Biochem. 2005, 69:246-248.
122. Jack D.L., Turner M.W. Anti-microbial activities of mannose-binding lectin. Biochem. Soc. Trans. 2003, 31:753-757.
123. Jatariu A., Peptu C., Popa M., Indrei A. Micro- and nanoparticles-medical applications. Rev. Med. Chir. Soc. Med. Nat. Iasi 2009, 113:1160-1169.
124. Johansen P., Men Y., Merkle H.P., Gander B. Revisiting PLA/PLGA microspheres: an analysis of their potential in parenteral vaccination. Eur. J. Pharm. Biopharm. 2000, 50:129-146.
125. Joshi M.D., Müller R.H. Lipid nanoparticles for parenteral delivery of actives. Eur. J. Pharm. Biopharm. 2009, 71:161-172.
126. Jung T., Kamm W., Breitenbach A., Hungerer K.D., Hundt E., Kissel T. Tetanus toxoid loaded nanoparticles from sulfobutylated poly(vinylalcohol)-graft-poly-(lactide-co-glycolide): evaluation of antibody response after oral and nasal application in mice. Pharm. Res. 2001, 18:352-360.
127. Junghanns J.U., Müller R.H. Nanocrystal technology, drug delivery and clinical applications. Int. J. Nanomed. 2008, 3:295-309.
128. Kataoka K., Harada A., Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv. Drug Deliv. Rev. 2001, 47:113-131.
129. Kilpatrick D.C. Mannan-binding lectin: clinical significance and applications. Biochim. Biophys. Acta 2002, 1572:401-413.
130. Kim S.Y., Doh H.J., Jang M.H., Ha Y.J., Chung S.I., Park H.J. Oral immunization with Helicobacter pylori-loaded poly(dl-lactide-co-glycolide) nanoparticles. Helicobacter 1999, 4:33-39.
131. Klajnert B., Bryszewska M. Dendrimers: properties and applications. Acta Biochem. Pol. 2001, 48:199-208.
132. Kopecek J., Kopeckova P., Minko T., Lu Z.R. HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action. Eur. J. Pharm. Biopharm. 2000, 50:61-81.
133. Krahenbuhl J.P., Neutra M.R. Epithelial M cells: differentiation and function. Annu. Rev. Cell Dev. Biol. 2000, 16:301-332.
134. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J. Controlled Release 2008, 132:171-183.
135. Kreuter J. Nanoparticles and nanocapsules. New dosage forms in the nanometer size range. Pharm. Acta Helv. 1978, 53:33-39.
136. Kreuter J. Evaluation of nanoparticles as drug-delivery systems II: Comparison of the body distribution of nanoparticles with the body distribution of microspheres (diameter greater than 1 micron), liposomes, and emulsions. Pharm. Acta Helv. 1983, 58:217-226.
137. Kreuter J. Nanoparticles. Encyclopedia of Pharmaceutical Technology 1994, Marcell and Dekker, New York. J. Swarbrick, J.C. Boylan (Eds.).
138. Kreuter J. Nanoparticles as drug delivery systems. Encyclopedia of Nanoscience and Nanotechnology 2004, American Scientific Publishers, Stevenson Ranch, U.S.A.
139. Kreuter J. Nanoparticles - a historical perspective. Int. J. Pharm. 2007, 331:1-10.
140. Kukowska-Latallo J.F., Raczka E., Quintana A., Chen C.L., Rymaszewski M., Baker J.R. Intravascular and endobronchial DNA delivery to murine lung tissue using a novel, nonviral vector. Hum. Gene Ther. 2000, 11:1385-1395.
141. Kumari A., Yadav S.K., Yadav S.C. Biodegradable polymeric nanoparticles based drug delivery systems. Colloid Surf. B: Biointerf. 2010, 75:1-18.
142. Kwon G.S. Polymeric micelles for delivery of poorly water-soluble compounds. Crit. Rev. Ther. Drug Carrier Syst. 2003, 20:357-403.
143. Labhasetwar V., Song C., Humphrey W., Shebuski R., Levy R.J. Arterial uptake of biodegradable nanoparticles: effect of surface modifications. J. Pharm. Sci. 1998, 87:1229-1234.
144. Lasic D.D. Novel applications of liposomes. Trends Biotechnol. 1998, 16:307-321.
145. Le Buanec H., Vetu C., Lachgar A., Benoit M.A., Gillard J., Paturance S., Aucoututier J., Gane V., Zaguri D., Bizzini B. Induction in mice of anti-Tat mucosal immunity by the intranasal and oral routes. Biomed. Pharmacother. 2001, 55:316-320.
146. Lecaroz C., Blanco-Prieto M.J., Burrell M.A., Gamazo C. Intracellular killing of Brucella melitensis in human macrophages with microsphere-encapsulated gentamicin. J. Antimicrob. Chemother. 2006, 58:549-556.
147. Lee S.E., Kim S.Y., Jeong B.C., Kim Y.R., Bae S.J., Ahn O.S., Lee J.J., Song H.C., Kim H., Choy H.E., Chung S.S., Kweon M.N., Rhee J.H. A bacterial flagellin, Vibrio vulnificus FlaB, has a strong mucosal adjuvant activity to induce protective immunity. Infect. Immun. 2006, 74:694-702.
148. Legrand P., Barratt G., Mosqueira V., Fessi H., Devissaguet J.P. Polymeric nanocapsules as drug delivery systems: a review. Sci. Tech. Pharm. 1999, 9:411-418.
149. Leite E.A., Grabe-Guimarães A., Guimarães H.N., Machado-Coelho G.L.L., Barratt G., Mosqueira V.C.F. Cardiotoxicity reduction induced by halofantrine entrapped in nanocapsule devices. Life Sci. 2007, 80:1327-1334.
150. Li C., Wallace S. Polymer-drug conjugates: recent development in clinical oncology. Adv. Drug Deliv. Rev. 2008, 60:886-898.
151. Lipinski C.A. Poor aqueous solubility: an industry wide problem in drug discovery. Am. Pharm. Rev. 2002, 5:82-85.
152. Lü J.M., Wang X., Marin-Muller C., Wang H., Lin P.H., Yao Q., Chen C. Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev. Mol. Diagn. 2009, 9:325-341.
153. Maham A., Tang Z., Wu H., Wang J., Lin Y. Protein-based nanomedicine platforms for drug delivery. Small 2009, 5:1706-1721.
154. Malik D.K., Baboota S., Ahuja A., Hasan S., Ali J. Recent advances in protein and peptide drug delivery systems. Curr. Drug Deliv. 2007, 4:141-151.
155. Masotti A., Ortaggi G. Chitosan micro- and nanospheres: fabrication and applications for drug and DNA delivery. Mini Rev. Med. Chem. 2009, 9:463-469.
156. Mehnert W., Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv. Drug Deliv. Rev. 2001, 47:165-196.
157. Merisko-Liversidge E., Liversidge G.G., Cooper E.R. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur. J. Pharm. Sci. 2003, 18:113-120.
158. Merisko-Liversidge E., Liversidge G.G. Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol. Patol. 2008, 36:43-48.
159. Merisko-Liversidge E., Liversidge G.G. Nanosizing for oral and parenteral drug delivery: A perspective on formulating poorly-water soluble compounds using wet media milling technology. Adv. Drug Deliv. Rev. 2011, 63:427-440.
160. Merodio M., Irache J.M., Eclancher F., Mirshahi M., Villarroya H. Distribution of albumin nanoparticles in animals induced with the experimental allergic encephalomyelitis. J. Drug Target. 2000, 8:289-303.
161. Merodio M., Arnedo A., Renedo M.J., Irache J.M. Ganciclovir-loaded albumin nanoparticles: characterization and in vitro release properties. Eur. J. Pharm. Sci. 2001, 12:251-259.
162. Merodio M., Espuelas M.S., Mirshahi M., Arnedo A., Irache J.M. Efficacy of ganciclovir-loaded nanoparticles in human cytomegalovirus (HCMV) infected cells. J. Drug Target. 2002, 10:231-238.
163. Merodio M., Irache J.M., Valamanesh F., Mirshahi M. Ocular disposition and tolerance of ganciclovir-loaded albumin nanoparticles after intravitreal injection in rats. Biomaterials 2002, 23:1587-1594.
164. Merodio M., Ruiz J., Bustos M., Martínez-Galan F., Campanero M.A., Irache J.M. Encapsulation of ganciclovir in albumin nanoparticles enhances the thymidine kinase suicide gene therapy. J. Drug Deliv. Sci. Technol. 2005, 14:121-127.
165. Mintzer M.A., Grinstaff M.W. Biomedical applications of dendrimers: a tutorial. Chem. Soc. Rev. 2011, 40:173-190.
166. Miyake A., Akagi T., Enose Y., Ueno M., Kawamura M., Horiuchi R., Hiraishi R., Adachi M., Srizawa T., Narayan O., Akshi M., Baba M., Hayami M. Induction of HIV-specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV-capturing nanospheres in macaques. J. Med. Virol. 2004, 73:368-377.
167. Moghimi S.M., Hunter A.C. Poloxamers and poloxamines in nanoparticle engineering and experimental medicine. Trends Biotechnol. 2000, 18:412-420.
168. Moghimi S.M., Hunter A.C., Murray J.C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 2001, 53:283-318.
169. Moghimi S.M., Hunter A.C. Recognition by macrophages and liver cells of opsonized phospholipid vesicles and phospholipid head groups. Pharm. Res. 2001, 18:1-8.
170. Moghimi S.M., Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid Res. 2003, 42:463-478.
171. Moghimi S.M., Hunter A.C., Murray J.C. Nanomedicine: current status and future prospects. FASEB J. 2005, 19:11-30.
172. Mok H., Park T.G. Functional polymers for targeted delivery of nucleic acid drugs. Macromol. Biosci. 2009, 9:731-743.
173. Mosqueira V.C.F., Loiseau P.M., Bories C., Legrand P., Devissaguet J.P., Barratt G. Efficacy and pharmacokinetics of intravenous nanocapsule formulations of halofantrine in Plasmodium berghei-infected mice. Antimicrob. Agents Chemother. 2004, 48:1222-1228.
174. Müller, R.H., Lucks, J.S., 1996. Arzneistoffträger aus festen Lipidteilchen, Feste Lipidnanosphären (SLN). European Patent No. 0605497.
175. Müller R.H., Mäder K., Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur. J. Pharm. Biopharm. 2000, 50:161-177.
176. Müller R.H. Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect in the future. Adv. Drug Deliv. Rev. 2001, 47:3-19.
177. Müller R.H., Radtke M., Wissing S.A. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv. Drug Deliv. Rev. 2002, 54:S131-S155.
178. Mozarafi M.R. Liposomes: an overview of manufacturing techniques. Cell. Mol. Biol. Lett. 2005, 10:711-719.
179. Munn L.L. Aberrant vascular architecture in tumours and its importance in drug-based therapies. Drug Discov. Today 2003, 8:396-403.
180. Murillo M., Gamazo C., Irache J.M., Goñi M.M. Polyester microparticles as a vaccine delivery system for brucellosis: influence of the polymer on release, phagocytosis and toxicity. J. Drug Target. 2002, 10:211-219.
181. Nagpal K., Singh S.K., Mishra D.N. Chitosan nanoparticles: a promising system in novel drug delivery. Chem. Pharm. Bull. (Tokyo) 2010, 58:1423-1430.
182. Nahar M., Jain N.K. Preparation, characterization and evaluation of targeting potential of amphotericin B-loaded engineered PLGA nanoparticles. Pharm. Res. 2009, 26:2588-2598.
183. Nayak B., Panda A.K., Ray P., Ray A.R. Formulation, characterization and evaluation of rotavirus encapsulated PLA and PLGA particles for oral vaccination. J. Microencapsul. 2009, 26:154-165.
184. Nechaeva E.A., Varaksin N., Ryabicheva T., Smolina M., Kolokoltsova T., Vilesov A., Aksenova N., Stankevich R., Isidorov R. Approaches to development of microencapsulated form of the live measles vaccine. Ann. N. Y. Acad. Sci. 2001, 944:180-186.
185. Nechaeva E. Development of oral microencapsulated forms for delivering viral vaccines. Exp. Rev. Vaccines 2002, 1:385-397.
186. Niwa T., Takeuchi H., Hino T., Kunou N., Kawashima Y. Preparations of biodegradable nanospheres of water-soluble and insoluble drugs with dl-lactide/glycolide copolymer by a novel spontaneous emulsification solvent diffusion method, and the drug release behaviour. J. Controlled Release 1993, 25:89-98.
187. Noguchi Y., Wu J., Duncan R., Strohalm J., Ulbrich K., Akaike T., Maeda H. Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn. J. Cancer Res. 1998, 89:307-314.
188. Noyes A.A., Whitney W.R. The rate of solution of solid substances in their own solutions. J. Am. Chem. Soc. 1897, 19:930-934.
189. Nyman D.W., Campbell K.J., Hersh E., Long K., Richardson K., Trieu V., Desai N., Hawkins M.J., Von Hoff D.D. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J. Clin. Oncol. 2005, 23:7785-7793.
190. O'Hagan D.T., McGee J.P., Lindblad M., Holmgren J. Cholera toxin B subunit (CTB) entrapped in microparticles shows comparable immunogenicity to CTB mixed with whole cholera toxin following oral immunization. Int. J. Pharm. 1995, 119:251-255.
191. Ochoa-Reparaz J., Sesma B., Alvarez M., Renedo M.J., Irache J.M., Gamazo C. Humoral immune response in hens naturally infected with Salmonella Enteritidis against outer membrane proteins and other superficial structural antigens. Vet. Res. 2004, 35:291-298.
192. Ojer P., Salman H., Da Costa Martins R., Calvo J., Lopez de Cerain A., Gamazo C., Lavandera J.L., Irache J.M. Spray-drying of poly(anhydride) nanoparticles for drug/antigen delivery. J. Drug Deliv. Sci. Technol. 2010, 20:353-359.
193. Oowaki H., Matsuda S., Sakai N., Ohta T., Iwata H., Sadato A., Taki W., Hashimoto N., Ikada Y. Non-adhesive cyanoacrylate as an embolic material for endovascular neurosurgery. Biomaterials 2000, 21:1039-1046.
194. Osada K., Kataoka K. Drug and gene delivery based on supramolecular assembly of PEG-polypeptide hybrid block copolymers. Adv. Polym. Sci. 2006, 202:113-153.
195. Oyewumi M.O., Yokel R.A., Jay M., Coakley T., Mumper R.J. Comparison of cell uptake, biodistribution and tumor retention of folate-coated and PEG-coated gadolinium nanoparticles in tumor-bearing mice. J. Controlled Release 2004, 95:613-626.
196. Page-Clisson M.E., Pinto-Alphandary H., Chachaty E., Couvreur P., Andremont A. Drug targeting by polyalkylcyanoacrylate is not efficient against persistent Salmonella. Pharm. Res. 1998, 15:542-547.
197. Paleos C.M., Tsiourvas D., Sideratou Z., Tziveleka L.A. Drug delivery using multifunctional dendrimers and hyperbranched polymers. Expert Opin. Drug Deliv. 2010, 7:1387-1398.
198. Pandey R., Zahoor A., Sharma S., Khuller G.K. Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis. Tuberculosis (Edinb) 2003, 83:373-378.
199. Pandey R., Sharma A., Zahoor A., Sharma S., Khuller G.K., Prasad B. Poly (dl-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J. Antimicrob. Chemother. 2003, 52:981-986.
200. Pandey R., Khuller G.K. Antitubercular inhaled therapy: opportunities, progress and challenges. J. Antimicrob. Chemother. 2005, 55:430-435.
201. Pardeike J., Hommoss A., Müller R.H. Lipid nanoparticles (SLN NCL) in cosmetic and pharmaceutical dermal products. Int. J. Pharm. 2009, 366:170-184.
202. Pardridge W.M. Drug targeting to the brain. Pharm Res. 2007, 24:1733-1744.
203. Park J.H., Ye M., Park K. Biodegradable polymers for microencapsulation of drugs. Molecules 2005, 10:146-161.
204. Parveen S., Sahoo S.K. Polymeric nanoparticles for cancer therapy. J. Drug Target. 2008, 16:108-123.
205. Pasquier E., Kavallaris M., Andre N. Metronomic chemotherapy: new rationale for new directions. Nat. Rev. Clin. Oncol. 2010, 7:455-465.
206. Patel J., Galey D., Jones J., Ray P., Woodward J.G., Nath A., Mumper R.J. HIV-1 Tat-coated nanoparticles result in enhanced humoral immune responses and neutralizing antibodies compared to alum adjuvant. Vaccine 2006, 24:3564-3573.
207. Peracchia M.T., Vauthier C., Desmaele D., Gulik A., Dedieu J.C., Demoy M., D'Angelo J., Couvreur P. Pegylated nanoparticles from a novel methoxypolyethylene glycol cyanoacrylate-hexadecyl cyanoacrylate amphiphilic copolymer. Pharm. Res. 1998, 15:550-556.
208. Peracchia M.T., Harnisch S., Pinto-Alphandary H., Gulik A., Dedieu J.C., Desmaele D., D'Angelo J., Muller R.H., Couvreur P. Visualization of in vitro protein-rejecting properties of PEGylated stealth polycyanoacrylate nanoparticle. Biomaterials 1999, 20:1269-1275.
209. Pinto-Alphandary H., Andremont A., Couvreur P. Targeted delivery of antibiotics using liposomes and nanoparticles: research and applications. Int. J. Antimicrob. Agents 2000, 13:155-168.
210. Ponchel G., Irache J.M. Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract. Adv. Drug Deliv. Rev. 1998, 34:191-219.
211. Prego C., Torres D., Fernadez-Megia E., Novoa-Carballal R., Quiñoa E., Alonso M.J. Chitosan-PEG nanocapsules as new carriers for oral peptide delivery. Effect of chitosan pegylation degree. J. Controlled Release 2006, 111:299-308.
212. Prior S., Gander B., Blarer N., Merkle H.P., Subira M.L., Irache J.M., Gamazo C. In vitro phagocytosis and monocyte-macrophage activation with poly(lactide) and poly(lactide-co-glycolide) microspheres. Eur. J. Pharm. Sci. 2002, 15:197-207.
213. Prior S., Gander B., Lecaroz C., Irache J.M., Gamazo C. Gentamicin-loaded microspheres for reducing the intracellular Brucella abortus load in infected monocytes. J. Antimicrob. Chemother. 2004, 53:981-988.
214. Pushkar S., Philip A., Pathak K., Pathak D. Dendrimers: nanotechnology derived novel polymers in drug delivery. Indian J. Pharm. Educ. Res. 2006, 40:153-158.
215. Rajesh Kumar S., Ishaq Ahmed V.P., Parameswaran V., Sudhakaran R., Sarath Babu V., Sahul Hameed A.S. Potential use of chitosan nanoparticles for oral delivery of DNA vaccine in Asian sea bass (Lates calcarifer) to protect from Vibrio (Listonella) anguillarum. Fish Shellfish Immunol. 2008, 25:47-56.
216. Rajesh Kumar S., Venkatesan C., Sarathi M., Sarathbabu V., Thomas J., Anver Basha K., Sahul Hameed A.S. Oral delivery of DNA construct using chitosan nanoparticles to protect the shrimp from white spot syndrome virus (WSSV). Fish Shellfish Immunol. 2009, 26:429-437.
217. Rapoport N. Physical stimuli-responsive polymeric micelles for anti-cancer drug delivery. Prog. Polym. Sci. 2007, 32:962-990.
218. Read R.C., Naylor S.C., Potter C.W., Bond J., Jabbal-Gill I., Fisher A., Illum L., Jennings R. Effective nasal influenza vaccine delivery using chitosan. Vaccine 2005, 23:4367-4374.
219. Remy J.S., Kichler A., Mordvinov V., Chuber F., Behr J.P. Targeted gene transfer into hepatoma cells with lipopolyamine-condensed DNA particles presenting galactose ligands: a stage toward artificial viruses. Proc. Natl. Acad. Sci. USA 1995, 92:1744-1748.
220. Rihova B., Kubackova K. Clinical implications of N-(2-hydroxypropyl)methacrylamide copolymers. Curr. Pharm. Biotechnol. 2003, 4:311-322.
221. Ríhová B., Strohalm J., Prausová J., Kubácková K., Jelínková M., Rozprimová L., Sírová M., Plocová D., Etrych T., Subr V., Mrkvan T., Kovár M., Ulbrich K. Cytostatic and immunomobilizing activities of polymer-bound drugs: experimental and first clinical data. J. Controlled Release 2003, 28:1-16.
222. Ringsdorf H. Structure and properties of pharmacologically active polymers. J. Polym. Sci. Polym. Symp. 1975, 51:135-153.
223. Rodríguez-Hernández J., Chécot F., Gnanou Y., Lecommandoux S. Toward "smart" nano-objects by self-assembly of block copolymers in solution. Prog. Polym. Sci. 2005, 30:691-724.
224. Rose P. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer. Oncologist 2005, 10:205-214.
225. Rowe R.C., Sheskey P.J., Quinn M.E. Handbook of Pharmaceutical Excipients 2009, Pharmaceutical Press. 6th ed.
226. Sahoo S.K., Parveen S., Panda J.J. The present and future of nanotechnology in human health care. Nanomed.-Nanotechnol. Biol. Med. 2007, 3:20-31.
227. Sakthivel T., Florence A.T. Adsorption of amphipathic dendrons on polystyrene nanoparticles. Int. J. Pharm. 2003, 254:23-26.
228. Salman H., Gamazo C., Campanero M.A., Irache J.M. Salmonella-like bioadhesive nanoparticles. J. Controlled Release 2005, 106:1-13.
229. Salman H., Gamazo C., de Smidt C., Russell-Jones G., Irache J.M. Evaluation of bioadhesive capacity and immunoadjuvant properties of vitamin B12-Gantrez nanoparticles. Pharm. Res. 2008, 25:2859-2868.
230. Salman H., Gómez S., Gamazo C., Da Costa Martins R., Zabaleta V., Irache J.M. Microorganism-like nanoparticles for oral antigen delivery. J. Drug Deliv. Sci. Technol. 2008, 18:31-39.
231. Salman H., Irache J.M., Gamazo C. Immunoadjuvant capacity of flagellin and mannosamine coated poly(anhydride) nanoparticles in oral vaccination. Vaccine 2009, 27:4784-4790.
232. Santos-Magalhaes N.S., Mosquiera V.C. Nanotechnology applied to the treatment of malaria. Adv. Drug Deliv. Rev. 2010, 62:560-575.
233. Sapra P., Allen T.M. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody targeted liposomal drugs. Cancer Res. 2002, 62:7190-7194.
234. Schellens J.H., Malingre M.M., Kruijtzer C.M., Bardelmeijer H.A., van Tellingen O., Schinkel A.H., Beijnen J.H. Modulation of oral bioavailability of anticancer drugs: from mouse to man. Eur. J. Pharm. Sci. 2000, 12:103-110.
235. Schiffelers R., Storm G., Bakker-Woudenberg I. Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies. J. Antimicrob. Chemother. 2001, 48:333-344.
236. Scholes P.D., Coombes A.G.A., Illum L., Davis S.S., Vert M., Davies M.C. The preparation of sub-200nm poly (lactide-co-glycolide) microspheres for site-specific drug delivery. J. Controlled Release 1993, 25:145-153.
237. Segura S., Gamazo C., Irache J.M., Espuelas S. Gamma interferon loaded onto albumin nanoparticles: in vitro and in vivo activities against Brucella abortus. Antimicrob. Agent Chemother. 2007, 51:1310-1314.
238. Seleem M.N., Jain N., Pothayee N., Ranjan A., Riffle J.S., Sriranganathan N. Targeting Brucella melitensis with polymeric nanoparticles containing streptomycin and doxycycline. FEMS Microbiol. Lett. 2009, 294:24-31.
239. Sezgin Z., Yüksel N., Baykara T. Preparation and characterization of polymeric micelles for solubilization of poorly soluble anticancer drugs. Eur. J. Pharm. Biopharm. 2006, 64:261-268.
240. Sharma A., Pandey R., Sharma S., Khuller G.K. Chemotherapeutic efficacy of poly (dl-lactide-co-glycolide) nanoparticle encapsulated antitubercular drugs at sub-therapeutic dose against experimental tuberculosis. Int. J. Antimicrob. Agents 2004, 24:599-604.
241. Sharma A., Sharma S., Khuller G.K. Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J. Antimicrob. Chemother. 2004, 54:761-766.
242. Shive M.S., Anderson J.M. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv. Drug Deliv. Rev. 1997, 28:5-24.
243. Singh R., Singh S., Lillard J.W. Past, present and future technologies for oral delivery of therapeutic proteins. J. Pharm. Sci. 2008, 97:2497-2523.
244. Singh M., Manikandan S., Kumaraguru A.K. Nanoparticles: a new technology with wide applications. Res. J. Nanosci. Nanotechnol. 2011, 1:1-11.
245. Sirova M., Strohalm J., Subr V., Plocova D., Rossmann P., Mrkvan T., Ulbrich K., Rihova B. Treatment with HPMA copolymer-based doxorubicin conjugate containing human immunoglobulin induces long-lasting systemic anti-tumour immunity in mice. Cancer Immunol. Immunother. 2007, 56:35-47.
246. Soma C.E., Dubernet C., Barratt G., Nemati F., Appel M., Benita S., Couvreur P. Ability of doxorubicin-loaded nanoparticles to overcome multidrug resistance of tumor cells after their capture by macrophages. Pharm. Res. 1999, 16:1710-1716.
247. Soppimatha K.S., Aminabhavia T.M., Kulkarnia A.R., Rudzinski W.E. Biodegradable polymeric nanoparticles as drug delivery devices. J. Controlled Release 2001, 70:1-20.
248. Stella B., Arpicco S., Peracchia M., Desmaele D., Hoebeke J., Renoir M., D'Angelo J., Cattel L., Couvreur P. Design of folic acid-conjugated nanoparticles for drug targeting. J. Pharm. Sci. 2000, 89:1452-1464.
249. Storni T., Kundig T.M., Senti G., Johansen P. Immunity in response to particulate antigen-delivery systems. Adv. Drug Deliv. Rev. 2005, 57:333-355.
250. Strickley R.G. Solubilizing excipients in oral and injectable formulations. Pharm. Res. 2004, 21:201-230.
251. Sun X., Zhang N. Cationic polymer optimization for efficient gene delivery. Mini Rev. Med. Chem. 2010, 10:108-125.
252. Tamayo I., Irache J.M., Mansilla C., Ochoa-Repáraz J., Lasarte J.J., Gamazo C. Poly(anhydride) nanoparticles act as active Th1 adjuvants through TLR exploitation. Clin. Vaccine Immunol. 2010, 17:1356-1362.
253. Terwogt J.M., Schellens J.H., Huinink W.W., Beijnen J.H. Clinical pharmacology of anticancer agents in relation to formulations and administration routes. Cancer Treat. Rev. 1999, 25:83-101.
254. Thioune O., Fessi H., Devissaguet J.P., Puisieux F. Preparation of pseudolatex by nanoprecipitation: Influence of the solvent nature on intrinsic viscosity and interaction constant. Int. J. Pharm. 1997, 146:233-238.
255. Tian X.H., Ling X.N., Wei F., Feng W., Huang Z.C., Wang P., Ren L., Diao Y. Enhanced brain targeting of temozolomide in polysorbate-80 coated polybutylcyanoacrylate nanoparticles. Int. J. Nanomed. 2011, 6:445-452.
256. Tobio M., Gref R., Sanchez A., Langer R., Alonso M.J. Stealth PLA-PEG nanoparticles as protein carriers for nasal administration. Pharm. Res. 1998, 15:270-2075.
257. Tomalia D.A. Birth of new molecular architecture: dendrimers as quantized building blocks for nanoscale synthetic polymer chemistry. Prog. Polym. Sci. 2005, 30:294-324.
258. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 2005, 4:145-160.
259. Torchilin V.P. Micellar nanocarriers: pharmaceutical perspectives. Pharm. Res. 2007, 24:1-16.
260. Trivedi R., Kompella U.B. Nanomicellar formulations for sustained drug delivery: strategies and underlying principles. Nanomedicine (Lond.) 2010, 5:485-505.
261. Tros de Ilarduya C., Sun Y., Düzgüneş N. Gene delivery by lipoplexes and polyplexes. Eur. J. Pharm. Sci. 2010, 40:159-170.
262. Tröster S.D., Kreuter J. Influence of the surface properties of low contact angle surfactants on the body distribution of 14C-poly(methyl methacrylate) nanoparticles. J. Microencapsul. 1992, 9:19-28.
263. Tyagi R., Lala S., Verma A.K., Nandy A.K., Mahato S.B., Maitra A., Basu M.K. Targeted delivery of arjunglucoside I using surface hydrophilic and hydrophobic nanocarriers to combat experimental leishmaniasis. J. Drug Target. 2005, 13:161-171.
264. Uemura K., Ska M., Nakagawa T., Kawasaki N., Thiel S., Jensenius J.C., Kawasaki T. L-MBP is expressed in epithelial cells of mouse small intestine. J. Immunol. 2002, 169:6945-6950.
265. Vakil R., Kwon G.S. Poly(ethylene glycol)-β-poly(e{open}-caprolactone) and PEG-phospholipid form stable mixed micelles in aqueous media. Langmuir 2006, 22:9723-9729.
266. Vandamme T.H.F., Brobeck L. Poly(amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide. J. Controlled Release 2005, 102:23-38.
267. Vauthier C., Dubernet C., Chauvierre C., Brigger I., Couvreur P. Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles. J. Controlled Release 2003, 93:151-160.
268. Vauthier C., Bouchemal K. Methods for the preparation and manufacture of polymeric nanoparticles. Pharm. Res. 2008, 26:1025-1058.
269. Verdun C., Brasseur F., Vranckx H., Couvreur P., Roland M. Tissue distribution of doxorubicin associated with polyhexylcyanoacrylate nanoparticles. Cancer Chemother. Pharmacol. 1990, 26:13-18.
270. Vicent M.J., Duncan R. Polymer conjugates: nanosized medicines for treating cancer. Trends Biotechnol. 2006, 24:39-47.
271. Videira M.A., Botelho M.F., Santos A.C., Gouveia L.F., Pedroso de Lima J.J., Almeida A.J. Lymphatic uptake of radiolabelled solid lipid nanoparticles administered by the pulmonary route. J. Drug Target. 1999, 10:607-613.
272. Vila A., Sanchez A., Tobio M., Calvo P., Alonso M.J. Design of biodegradable particles for protein delivery. J. Controlled Release 2002, 78:15-24.
273. Vila A., Sanchez A., Evora C., Soriano I., Vila Jato J.L., Alonso M.J. PEG-PLA nanoparticles as carriers for nasal vaccine delivery. J. Aerosol. Med. 2004, 17:174-185.
274. Vila A., Sanchez A., Janes K., Behrens I., Kissel T., Vila Jato J.L., Alonso M.J. Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. Eur. J. Pharm. Biopharm. 2004, 57:123-131.
275. Vila A., Gill H., McCallion O., Alonso M.J. Transport of PLA-PEG particles across the nasal mucosa: effect of particle size and PEG coating density. J. Controlled Release 2004, 98:231-244.
276. Vitas A.I., Diaz R., Gamazo C. Effect of composition and method of preparation of liposomes on their stability and interaction with murine monocytes infected with Brucella abortus. Antimicrob. Agents Chemother. 1996, 40:146-151.
277. Volkheimer G., Schulz F.H. The phenomenon of persorption. Digestion 1968, 1:213-218.
278. Wagner S., Lynch N.J., Walter W., Schwaeble W.J., Loos M. Differential expression of the murine mannose-binding lectins A and C in lymphoid and non lymphoid organs and tissues. J. Immunol. 2003, 170:1462-1465.
279. Wartlick H., Michaelis K., Balthasar S., Strebhardt K., Kreuter J., Langer K. Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells. J. Drug Target. 2004, 12:461-471.
280. Webster T.J. Nanomedicine: what's in a definition?. Int J. Nanomed. 2006, 1:115-116.
281. Weingart S.N., Brown E., Bach P.B., Eng K., Johnson S.A., Kuzel T.M., Langbaum T.S., Leedy R.D., Muller R.J., Newcomer L.N., O'Brien S., Reinke D., Rubino M., Saltz L., Walters R.S. NCCN task force report: oral chemotherapy. J. Natl. Compr. Cancer Netw. 2008, 6:S1-14.
282. Win K.Y., Feng S.S. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 2005, 26:2713-2722.
283. Wolka A.M., Huber J.D., Davis T.P. Pain and the blood-brain barrier: obstacles to drug delivery. Adv. Drug Deliv. Rev. 2003, 55:987-1006.
284. Xu J., Dai W., Wang Z., Chan B., Li Z., Fan X. Intranasal vaccination with chitosan-DNA nanoparticles expressing pneumococcal surface antigen a protects mice against nasopharyngeal colonization by Streptococcus pneumoniae. Clin. Vaccine Immunol. 2011, 18:75-81.
285. Yiyun C., Zhenhua X., Minglu M., Tonguen X. Dendrimers as drug carriers: applications in different routes of drug. J. Pharm. Sci. 2008, 97:123-143.
286. Yiyun C.H., Tongwen X. Dendrimers as potential drug carriers, Part I. Solubilization of non-steroidal anti-inflammatory drugs in the presence of polyamidoamine dendrimers. Eur. J. Med. Chem. 2005, 40:1188-1192.
287. Yoncheva K., Gómez S., Campanero M.A., Gamazo C., Irache J.M. Bioadhesive properties of pegylated nanoparticles. Expert Opin. Drug Deliv. 2005, 2:205-218.
288. Yoncheva K., Lizarraga E., Irache J.M. Pegylated nanoparticles based on poly(methyl vinyl ether-co-maleic anhydride): preparation and evaluation of their bioadhesive properties. Eur. J. Pharm. Sci. 2005, 24:411-419.
289. Yoncheva K., Guembe L., Campanero M.A., Irache J.M. Evaluation of bioadhesive potential and intestinal transport of pegylated poly(anhydride) nanoparticles. Int. J. Pharm. 2007, 334:156-165.
290. Zambaux M.F., Bonneaux F., Gref R., Maincent P., Dellacherie E., Alonso M.J., Labrude P., Vigneron C. Influence of experimental parameters on the characteristics of PLA nanoparticles prepared by a double emulsion method. J. Controlled Release 1998, 50:31-40.
291. Zhang G.Z., Niu A., Peng S.F., Jiang M., Tu Y.F., Li M., Wu C. Formation of novel polymeric nanoparticles. Acc. Chem. Res. 2001, 34:249-256.
292. Zolle I., Hosain F., Rhodes B.A., Wagner H.N. Human serum albumin millimicrospheres for studies of reticuloendothelial system. J. Nucl. Med. 1970, 11:379-380.